[Blue Lotus Sector Update]: Solid Companies Starting to Rise from the Ashes
China's drug sector is driven by liquidity, with limited investment choices. Akeso and BeiGene are recommended as buy options, while RemeGen,...
449 Views
WuXi XDC Cayman IPO Trading - Strong Subscription Rates Heading into Listing
WuXi XDC Cayman (1877628D HK) raised US$470m in its Hong Kong IPO. In our previous notes, we looked at the company’s past performance and...
442 Views
WuXi XDC Cayman IPO - Decent Upside from IPO Range, Bulk of the Deal Taken up by Marquee Investors
WuXi XDC Cayman (1877628D HK) is looking to raise US$470m in its Hong Kong IPO. In this note, we will look at the deal dynamics and share our final...
638 Views
WuXi XDC Cayman Pre-IPO - BULL/BEAR Scenario Considerations for Valuations
WuXi XDC Cayman (1877628D HK) is looking to raise around US$500m in its upcoming Hong Kong IPO. In this note, we share our updated thoughts on...
401 Views
WuXi XDC Cayman Pre-IPO - PHIP Updates - Margins Remain Depressed Although Growth Still Strong
WuXi XDC Cayman Inc (1877628D HK) is looking to raise around US$500m in its upcoming Hong Kong IPO. In this note, we discuss WXDC’s PHIP updates.
373 Views